Capricor Therapeutics Inc. Common Stock (CAPR)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the numbers and ask whether there is a durable business. Capricor is a clinical-stage biotech with no approved product and no profit. Its lead candidate, Deramiocel, is in Phase 3 for Duchenne muscular dystrophy, but hope is not an earnings record. Filed figures show fiscal year 2023, period ended 2023-12-31, revenue of $25.2 million, and fiscal year 2024, period ended 2024-12-31, revenue of $22.3 million. Fiscal year 2025, period ended 2025-12-31, reported revenue N/A and a net loss of $105.0 million, or EPS -$2.26. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $33.9 million, EPS -$0.59; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $40.7 million, EPS -$0.70. Trailing free cash flow is -$129.8 million, a -32.4% FCF yield. FairStock ratios from the close of $6.88 on 2026-10-13 show P/B 1.62, P/E -2.81, ROE -73.70%, ROCE -33.63%, D/E 0.37, Piotroski 0/9, and Altman Z 1.16. That is not a balance sheet or income statement that offers a Graham margin of safety. The moat is unproven; biotechnology value comes from patents, trial data, regulatory approval, and reimbursement, none of which are in the filed financials. The market cap of $400 million prices in a successful pipeline, not present earnings. Until there is commercial traction, controlled cash burn, and a clear path to profitability, this is speculation, not a value investment.

In plain English: Capricor Therapeutics is an experimental medicine company working on cell-based treatments for Duchenne muscular dystrophy. The business looks weak right now: it has lost money for years and is spending much more than it brings in. At $6.88, the price mostly reflects hope that its treatments will work, so it does not look clearly cheap based on today's sales or profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer